Taiko Pharmaceutical Co., Ltd. (JP:4574)
:4574
Want to see JP:4574 full AI Analyst Report?
4574 Stock Chart & Stats
¥305.00
-¥2.00(-0.62%)
At close: 4:00 PM EST
¥305.00
-¥2.00(-0.62%)
Day’s Range― - ―
52-Week Range¥239.00 - ¥444.00
Previous CloseN/A
Volume146.60K
Average Volume (3M)93.84K
Market Cap
¥12.47B
Enterprise Value¥10.01B
Total Cash (Recent Filing)¥4.14B
Total Debt (Recent Filing)¥1.32B
Price to Earnings (P/E)23.3
Beta0.71
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.23
Shares Outstanding50,636,900
10 Day Avg. Volume93,940
30 Day Avg. Volume93,840
Financial Highlights & Ratios
PEG Ratio6.05
Price to Book (P/B)1.76
Price to Sales (P/S)2.34
P/FCF Ratio28.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.9
Revenue Forecast (FY)¥6.75B
Bulls Say, Bears Say
Bulls Say
Stronger Balance SheetMaterial debt reduction versus 2023–2024 meaningfully lowers financial risk and interest burden, improving flexibility to fund R&D, product launches, or strategic moves. A sizable equity base also provides a cushion to absorb cyclical shocks and support longer-term investments.
Positive Cash GenerationOperating and free cash flow turned positive and strengthened in 2024–2025, indicating improved cash conversion ability. Durable positive FCF supports reinvestment in pipelines, steady operations, and reduces reliance on external financing, enhancing long-term financial resilience.
Stable-to-Growing RevenueRevenue stabilization and sequential growth in 2024–2025 suggest recovering demand or better commercialization execution. Sustained top-line improvement improves margin leverage potential and supports repeatable cash generation, important for long-term profitability and funding of R&D.
Bears Say
Earnings VolatilityLarge swings from profit to heavy losses across recent years undermine earnings predictability and planning. This structural volatility complicates capital allocation, investor confidence, and sustained investment in pipeline or commercialization, raising execution risk over cycles.
Unproven Cash Conversion StabilityThough cash flows improved recently, historic negative operating cash flows through 2020–2023 and light 2024 conversion versus profits mean cash durability is not yet proven. This elevates risk that profits may not consistently translate to free cash for reinvestment or deleveraging.
Shrinking Asset Base & Past Poor ROEA declining asset base can constrain capacity and growth unless deliberate restructuring is underway. Combined with deeply negative ROE in recent years, this signals past inefficiencies and raises concern about the company's ability to generate durable returns on deployed capital moving forward.
Taiko Pharmaceutical Co., Ltd. News
4574 FAQ
What was Taiko Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Taiko Pharmaceutical Co., Ltd. lowest stock price was ¥239.00 and its highest was ¥444.00 in the past 12 months.
What is Taiko Pharmaceutical Co., Ltd.’s market cap?
Taiko Pharmaceutical Co., Ltd.’s market cap is ¥12.47B.
When is Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 65 days.
How were Taiko Pharmaceutical Co., Ltd.’s earnings last quarter?
Taiko Pharmaceutical Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥1.89 earnings per share for the quarter, missing the consensus estimate of N/A by -¥1.89.
Is Taiko Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Taiko Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Taiko Pharmaceutical Co., Ltd. pay dividends?
Taiko Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥13 which represents an annual dividend yield of N/A. See more information on Taiko Pharmaceutical Co., Ltd. dividends here
What is Taiko Pharmaceutical Co., Ltd.’s EPS estimate?
Taiko Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taiko Pharmaceutical Co., Ltd. have?
Taiko Pharmaceutical Co., Ltd. has 50,636,900 shares outstanding.
What happened to Taiko Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Taiko Pharmaceutical Co., Ltd. reported an EPS of -¥1.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of Taiko Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4574
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Taiko Pharmaceutical Co., Ltd.
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
Nippon Chemiphar Co., Ltd.
―